Hepatitis C virus elimination programme

Gilead launched an innovative donation programme with the goal of eliminating hepatitis C virus in Georgia.

Summary  

  • What: Gilead launched an innovative donation programme, donating its newly launched, patented, medicines sofosbuvir (Sovaldi®) and ledipasvir/sofosbuvir (Harvoni®). The programme includes universal screening, prevention, treatment and surveillance.
  • Objective: It aims to develop a national hepatitis C prevention and control plan, in order to eliminate hepatitis C virus (HCV) in Georgia.
  • Details: In 2015, Gilead provided 5,000 free courses of Sovaldi® to the government of Georgia and will provide 20,000 courses of Harvoni® each subsequent year.
  • Scope: People living with hepatitis C in Georgia.

Looking closer

In 2015, Gilead launched a donation programme with the goal of eliminating HCV in Georgia. Through this programme, and together with the U.S. Centers for Disease Control (CDC), Gilead is assisting the government in building a national HCV elimination plan which includes universal screening, prevention activities, treatment, and surveillance. It aims to eliminate hepatitis C virus in Georgia.

In 2015, Gilead donated 5,000 free courses of Sovaldi® to the government of Georgia and will provide 20,000 courses of Harvoni® each subsequent year.

This programme is considered innovative in the Access to Medicine Index 2016 as it is the first donation programme of its kind in targeting hepatitis C virus with the aim of national elimination. In addition, Gilead donate newly launched, patented medicines in this programme (Sovaldi® and Harvoni®), whereas most structured donation programmes donate older, off-patent products.

Sign up to receive updates about our work.

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close